



EXPRESS SCRIPTS®

**Express Scripts, Inc.  
Pharmacy and Therapeutics Committee  
Proceedings  
April 21, 2007**

**Drug Evaluations**

**A. lapatinib tablets (Tykerb®) GSK**

Tykerb is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors and who have received prior therapy including an anthracycline (e.g., doxorubicin, epirubicin), a taxane (e.g., paclitaxel, docetaxel), and trastuzumab. Tykerb reversibly inhibits both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and HER2 [ErbB2] tyrosine kinases intracellularly

- Documents summarizing clinical information on Tykerb and its place in therapy were reviewed.

**Conclusion:** Tykerb is considered a product that should be made available as medically indicated and prescribed.

**B. aliskiren tablets (Tekturna®) Novartis**

Tekturna, a direct renin inhibitor, is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Use with maximum doses of angiotensin converting enzyme inhibitors and angiotensin receptor blockers has not been adequately studied.

- Documents summarizing clinical information on Tekturna and its place in therapy were reviewed.

**Conclusion:** Tekturna is considered a product whose safety and efficacy demonstrate that it is a therapeutic alternative to other currently available therapies.

**C. lisdexamfetamine dimesylate capsules (Vyvanse™) Shire**

Vyvanse, a pro-drug of dextroamphetamine, is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who meet *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)* criteria for ADHD.

- Documents summarizing clinical information on Vyvanse and its place in therapy were reviewed.

**Conclusion:** Vyvanse is considered a product whose safety and efficacy demonstrate that it is a therapeutic alternative to other currently available therapies.